Skip to content
StockMarketAgent
Direct answer
MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs. Fair value range: low $737, high $1308, with mid-point at $1016.
Stock analysis

MCK MCK fair value $737–$1,308

MCK
By StockMarketAgent.AI team· supervised by
已分析: 2026-05-13下次更新: 2026-08-13Methodology v2.5Review: automatedArchetype: Mature compounder
View archive
股价
$725.17
▲ +290.95 (+40.12%)
公允价值
$1016
$737–$1308
评级
强力买入
confidence 79/100
上行空间
+40.1%
upside to fair value
安全边际
$863.70
MoS level · 15%
市值
$87.2B
P/E fwd 14.4
英文原文ZH
翻译期间显示英文原文
此报告尚未翻译。翻译队列赶上后请在几分钟内刷新。

§1 执行摘要

  • Composite fair value $1,016 with high case $1,308.
  • Implied upside of 40.1% to fair value.
  • Moat 9/10 · confidence 79/100 · Mature compounder.
  • Trades below fair value with a meaningful cushion to the midpoint.
Fair value
$1,016
Margin of safety
+28.6%
Confidence
79/100
Moat
9/10

Educational analysis only — not financial advice. Always do your own due diligence.

$725.17Price
Low $737.34
Mid $1,016.12
High $1,307.92

MCK trades against a final fair-value range of $737.34-$1,307.92, with the midpoint set by the accepted valuation synthesis rather than earlier draft model outputs.

  • Immense scale forming an entrenched
    Immense scale forming an entrenched oligopoly in US pharmaceutical distribution.
  • High barriers to entry due
    High barriers to entry due to extreme capital and regulatory requirements.
  • Cycle upside
    Aging demographics and expanded specialty drug approvals drive sustained volume growth.

§2 看空情景

A stress scenario combining severe legislative pressure on drug prices with a sustained high-interest-rate environment would squeeze margins. If operating margins dip below 1.0% and the WACCWACCWeighted average cost of capital. The blended after-tax discount rate applied to free cash flows in a DCF, reflecting both equity and debt financing costs. normalizes to a higher tier, intrinsic valueIntrinsic valueThe discounted present value of all cash a business will produce over its remaining life. The theoretical anchor for fair value, computed in practice as a range across explicit assumptions. regressions toward the $737 downside boundary.

该论点可能失败的方式

Major Retail Network Loss

· Low

The loss of a massive retail pharmacy network customer significantly impairs revenue volume and devastates operating leverage.

FV impact
-25%

Regulatory Margin Collapse

· Medium

Aggressive legislative action on drug pricing and PBM models compresses already razor-thin operating margins below 1.0%.

FV impact
-30%

Resurgent Litigation

· Low

Unexpected expansion of opioid-related liabilities or new mass torts drain free cash flow, threatening the share buyback program.

FV impact
-15%
需关注的早期预警信号
指标当前触发阈值
Operating margins slipping below 1.2% for consecutive quarters.MonitorDeterioration versus the report thesis
Cancellation or significant reduction of the annual share repurchase program.MonitorDeterioration versus the report thesis
Loss of major customer contracts in the retail pharmacy segment.MonitorDeterioration versus the report thesis
Slowing revenue growth in the higher-margin specialty oncology segment.MonitorDeterioration versus the report thesis
Deteriorating free cash flow conversion ratios.MonitorDeterioration versus the report thesis

§3 财务历史

损益表 — 最近六期
项目T−0T−1T−2T−3CAGR
期间2022-03-312023-03-312024-03-312025-03-31Trend
营业收入$263.97B$276.71B$308.95B$359.05B+10.8%
毛利$13.13B$12.36B$12.83B$13.32B+0.5%
营业利润$2.59B$4.58B$4.17B$4.82B+22.9%
净利润$1.11B$3.56B$3.00B$3.30B+43.5%
每股收益(摊薄)$7.23$25.03$22.39$25.72+52.7%
EBITDA$2.87B$5.49B$4.68B$5.26B+22.4%
研发
销售管理费用$10.54B$7.78B$8.66B$8.51B-6.9%

质量评分

OCF / 净利润
1.85×
>1 表示盈利质量高
会计质量门槛
Fail
经行业调整门槛
ROIC
68.7%
投入资本回报率
第 3 节

Numbers analysis

现金流

Cash-flow quality is reflected in the OCFOperating cash flowCash generated from the company's core operations after working-capital changes but before capital expenditures. The first line of the cash-flow statement. / net incomeNet IncomeNet Income is an income-statement line item used to reconcile revenue to operating profit, pre-tax income, net income, or per-share earnings. It should be compared across periods and against peer disclosure conventions., accounting-quality, and ROICROICReturn on invested capital. Operating profit (after tax) divided by invested capital. The single best gauge of capital-efficiency. Spread over WACC = economic value created. rows above.

资本配置

Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.

个人订阅用户 — §4 及之后还有 11 个章节

阅读完整分析 — 还有 11 个章节。

Competitive moat, industry cycle, peer comparison, intrinsic valuation, sensitivity, scenarios, earnings decision tree, position management, investor perspectives, scorecard, and final recommendation.

涵盖每个股票的完整报告
24 个月的评级存档
关注列表简报 + 评级变更提醒
以任意语言导出 PDF + DOCX
开始免费试用
可随时取消。
FAQ

MCK — frequently asked questions

  1. Based on our latest analysis, MCK looks meaningfully undervalued. The current price is $725 versus a composite fair-value midpoint of $1016 (range $737–$1308), which implies roughly 40.1% upside to the midpoint.
Related coverage

Names readers of MCK also follow

Same archetype: mature-compounder